145 related articles for article (PubMed ID: 38617448)
21. A novel endoplasmic reticulum stress-related lncRNA signature for prognosis prediction and immune response evaluation in Stomach adenocarcinoma.
Song Z; Su M; Li X; Xie J; Han F; Yao J
BMC Gastroenterol; 2023 Dec; 23(1):432. PubMed ID: 38066437
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive analyses of a tumor-infiltrating lymphocytes-related gene signature regarding the prognosis and immunologic features for immunotherapy in bladder cancer on the basis of WGCNA.
He Z; Gu J; Luan T; Li H; Li C; Chen Z; Luo E; Wang J; Huang Y; Ding M
Front Immunol; 2022; 13():973974. PubMed ID: 36211333
[TBL] [Abstract][Full Text] [Related]
23. Construction and validation of a novel signature based on epithelial-mesenchymal transition-related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment.
Gao B; Wang Y; Lu S
Funct Integr Genomics; 2022 Dec; 23(1):6. PubMed ID: 36536232
[TBL] [Abstract][Full Text] [Related]
24. Development of a novel prognostic signature based on single-cell combined bulk RNA analysis in breast cancer.
Xiao Y; Hu G; Xie N; Yin L; Pan Y; Liu C; Lou S; Zhu C
J Gene Med; 2024 Feb; 26(2):e3673. PubMed ID: 38404059
[TBL] [Abstract][Full Text] [Related]
25. Identification of a necroptosis-related prognostic gene signature associated with tumor immune microenvironment in cervical carcinoma and experimental verification.
Sun K; Huang C; Li JZ; Luo ZX
World J Surg Oncol; 2022 Oct; 20(1):342. PubMed ID: 36253777
[TBL] [Abstract][Full Text] [Related]
26. Developing an m5C regulator-mediated RNA methylation modification signature to predict prognosis and immunotherapy efficacy in rectal cancer.
Zhang R; Gan W; Zong J; Hou Y; Zhou M; Yan Z; Li T; Lv S; Zeng Z; Wang W; Zhang F; Yang M
Front Immunol; 2023; 14():1054700. PubMed ID: 36911744
[TBL] [Abstract][Full Text] [Related]
27. A 13-gene signature to predict the prognosis and immunotherapy responses of lung squamous cell carcinoma.
Yang Q; Gong H; Liu J; Ye M; Zou W; Li H
Sci Rep; 2022 Aug; 12(1):13646. PubMed ID: 35953696
[TBL] [Abstract][Full Text] [Related]
28. Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients.
Hu B; Meng Y; Qu C; Wang BY; Xiu DR
Front Immunol; 2022; 13():1018413. PubMed ID: 36300104
[TBL] [Abstract][Full Text] [Related]
29. A novel immunogenic cell death-related genes signature for predicting prognosis, immune landscape and immunotherapy effect in hepatocellular carcinoma.
Xu G; Jiang Y; Li Y; Ge J; Xu X; Chen D; Wu J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16261-16277. PubMed ID: 37698679
[TBL] [Abstract][Full Text] [Related]
30. Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.
Lv Y; Wu L; Jian H; Zhang C; Lou Y; Kang Y; Hou M; Li Z; Li X; Sun B; Zhou H
Front Immunol; 2022; 13():997765. PubMed ID: 36275664
[TBL] [Abstract][Full Text] [Related]
31. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
Front Immunol; 2022; 13():933241. PubMed ID: 36211378
[TBL] [Abstract][Full Text] [Related]
32. Construction and validation of a novel lysosomal signature for hepatocellular carcinoma prognosis, diagnosis, and therapeutic decision-making.
Chen J; Gao G; He Y; Zhang Y; Wu H; Dai P; Zheng Q; Huang H; Weng J; Zheng Y; Huang Y
Sci Rep; 2023 Dec; 13(1):22624. PubMed ID: 38114725
[TBL] [Abstract][Full Text] [Related]
33. Prediction of Prognosis and Immunotherapy Response with a Novel Natural Killer Cell Marker Genes Signature in Osteosarcoma.
Li Q; Huang X; Zhao Y
Cancer Biother Radiopharm; 2023 Oct; ():. PubMed ID: 37889617
[No Abstract] [Full Text] [Related]
34. An Activated Dendritic-Cell-Related Gene Signature Indicative of Disease Prognosis and Chemotherapy and Immunotherapy Response in Colon Cancer Patients.
Ouyang Y; Yu M; Liu T; Suo M; Qiao J; Wang L; Li N
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958942
[TBL] [Abstract][Full Text] [Related]
35. Identification of a tumor microenvironment-related seven-gene signature for predicting prognosis in bladder cancer.
Wang Z; Tu L; Chen M; Tong S
BMC Cancer; 2021 Jun; 21(1):692. PubMed ID: 34112144
[TBL] [Abstract][Full Text] [Related]
36. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.
Chen J; Liao Y; Li R; Luo M; Wu G; Tan R; Xiao Z
Technol Cancer Res Treat; 2022; 21():15330338221090093. PubMed ID: 35509211
[No Abstract] [Full Text] [Related]
38. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
39. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
40. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
